The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chutko L.S.

Institut mozga cheloveka RAN im. N.P. Bekhterevoĭ, Sankt-Peterburg;
Sankt-Peterburgskaia gosudarstvennaia pediatricheskaia meditsinskaia akademiia

Surushkina S.Yu.

Institut mozga cheloveka RAN im. N.P. Bekhterevoĭ, Sankt-Peterburg;
Sankt-Peterburgskaia gosudarstvennaia pediatricheskaia meditsinskaia akademiia

Yakovenko E.A.

Institut mozga cheloveka RAN im. N.P. Bekhterevoĭ, Sankt-Peterburg

Anisimova T.I.

Institut mozga cheloveka RAN im. N.P. Bekhterevoĭ, Sankt-Peterburg;
Sankt-Peterburgskaia gosudarstvennaia pediatricheskaia meditsinskaia akademiia

Karpovskaya E.B.

St. Petersburg State Pediatric Medical University, of the Ministry of Healthcare of the Russian Federation, St.-Petersburg, Russia

Vasilenko V.V.

St. Petersburg State Pediatric Medical University, of the Ministry of Healthcare of the Russian Federation, St.-Petersburg, Russia

Didur M.D.

N. Bekhtereva Institute of the Human Brain Russian Academy of Sciences, St.-Petersburg, Russia

Volov M.B.

Bekhtereva Institute of Human Brain Russian Academy of Sciences, St. Petersburg, Russia

Impairments of cognitive control in patients with somatoform disorders and their treatment

Authors:

Chutko L.S., Surushkina S.Yu., Yakovenko E.A., Anisimova T.I., Karpovskaya E.B., Vasilenko V.V., Didur M.D., Volov M.B.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4): 32‑37

DOI: 10.17116/jnevro201911904132

Read: 2533 times

Download PDF (RU)
Contact the author
Table of contents

IMPAIRMENTS OF COGNITIVE CONTROL IN PATIENTS WITH SOMATOFORM DISORDERS AND THEIR TREATMENT
IMPAIRMENTS OF COGNITIVE CONTROL IN PATIENTS WITH SOMATOFORM DISORDERS AND THEIR TREATMENT

To cite this article:

Chutko LS, Surushkina SYu, Yakovenko EA, et al. Impairments of cognitive control in patients with somatoform disorders and their treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):32‑37. (In Russ.)
https://doi.org/10.17116/jnevro201911904132

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cognitive impairment in asthenic diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):27-32
The possibility of using neurotropic therapy in patients with persistent postural-perceptual dizziness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):89-94
Effi­cacy of Reco­gnan in the therapy of neurological diso­rders after traumatic brain injury. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):41-45
Hysterical diso­rders in patients with hema­tological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):71-78
The problem of digi­tal overload: cognitive impairments in young people. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):140-144
Atte­ntion defi­cit diso­rder in adults: features of social and family rela­tionships. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(1):13-18
Abstract:

Objective. To study impairments of cognitive control in patients with somatoform disorders (SD) and to evaluate the efficacy of recognan in the treatment of this pathology. Materials and methods. Forty-six patients with SD, aged from 18 to 45 years, were studied. A clinical history, neurological examination, and assessment of autonomic disorders were collected from all patients. For the objectification of the severity of asthenic and emotional disorders, the Subjective Scale of Asthenia (MFI-20), the Hamilton Anxiety Scale (HARS), the Cognitive Emotion Regulation Questionnaire (CERQ were used. A quantitative assessment of impaired attention and impulsivity was performed using the psychophysiological test TOVA. Patients were treated with recognan (citicoline). The control group consisted of 30 healthy people aged from 18 to 45 years. Results and conclusion. Patients with SD had specific characteristics of the cognitive sphere, most pronounced in the form of attention disorders. The psychological study showed the higher level of anxiety. In addition, patients with SD were characterized by the low levels of emotional intelligence and cognitive control of emotions compared with the control group. The results of the follow-up study after treatment suggest the high efficacy of recognan in the treatment of SD (improvement was noted in 67.4% of patients). A significant decrease in the severity of autonomic disorders and in indicators characterizing asthenia was established after the treatment.

Keywords:

somatoform disorders
cognitive control
recognan

Authors:

Chutko L.S.

Institut mozga cheloveka RAN im. N.P. Bekhterevoĭ, Sankt-Peterburg;
Sankt-Peterburgskaia gosudarstvennaia pediatricheskaia meditsinskaia akademiia

Surushkina S.Yu.

Institut mozga cheloveka RAN im. N.P. Bekhterevoĭ, Sankt-Peterburg;
Sankt-Peterburgskaia gosudarstvennaia pediatricheskaia meditsinskaia akademiia

Yakovenko E.A.

Institut mozga cheloveka RAN im. N.P. Bekhterevoĭ, Sankt-Peterburg

Anisimova T.I.

Institut mozga cheloveka RAN im. N.P. Bekhterevoĭ, Sankt-Peterburg;
Sankt-Peterburgskaia gosudarstvennaia pediatricheskaia meditsinskaia akademiia

Karpovskaya E.B.

St. Petersburg State Pediatric Medical University, of the Ministry of Healthcare of the Russian Federation, St.-Petersburg, Russia

Vasilenko V.V.

St. Petersburg State Pediatric Medical University, of the Ministry of Healthcare of the Russian Federation, St.-Petersburg, Russia

Didur M.D.

N. Bekhtereva Institute of the Human Brain Russian Academy of Sciences, St.-Petersburg, Russia

Volov M.B.

Bekhtereva Institute of Human Brain Russian Academy of Sciences, St. Petersburg, Russia

Close metadata

References:

  1. Veyn AM, Voznesenskaya TG, Golubev VL. Zabolevaniya vegetativnoy nervnoy sistemyi. M. 1991. (In Russ.)
  2. Morton L, Elliott A, Cleland J, Deary V, Burton C. A taxonomy of explainations in a general practitioner clinic for patients with persistent «medically unexplained» psysical symptoms. Patient Educ Counsel. 2017;100:224-230. https://doi.org/10.1016/j.pec.2016.08.015
  3. Pohontsch NJ, Zimmermann T, Jonas C, Lehmann M, Löwe B, Scherer M. Coding of medically unexplained symptoms and somatoform disorders by general practitioners — an exploratory focus group study. BMC Fam Pract. 2018;19(1):129. https://doi.org/10.1186/s12875-018-0812-8
  4. Van Driel TJW, Hilderink PH, Hanssen DJC, De Boer P, Rosmalen JGM, Oude Voshaar RC. Assessment of somatization and medically unexplained symptoms in later life. Assessment. 2018;25:374-393. https://doi.org/10.1177/1073191117721740
  5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.
  6. Steinbrecher N, Koerber S, Frieser D. The prevalence of medically unexplained symptoms in primary care. Psychosomatics. 2011;52:263-271. https://doi.org/10.1016/j.psym.2011.01.007
  7. Haller H, Cramer H, Lauche R. Somatoform disorders and medically unexplained symptoms in primary care. Dtsch Arztebl Int. 2015;112:279-287. https://doi.org/10.3238/arztebl.2015.0279
  8. Mitscherlich A. The mechanism of bi-phasic defense in psychosomatic diseases. Int J Psychoanal. 1968;49:236-240.
  9. Alexander F. Psychosomatic Medicine. Its principles and applications. London. 1952.
  10. Kholmogorova AB. Integrativnaya psikhoterapiya rasstroistv affektivnogo spektra. M.: Medpraktika-M; 2011. (In Russ.)
  11. Barsky AJ, Borus JF. Somatization and me dicalization in the era of managed care. JAMA. 1995;274:1931-1934. https://doi.org/10.1001/jama.1995.03530240041038
  12. Rief W, Barsky AJ. Psychobiological perspectives on somatoform disorders. Psychoneuroendocrinology. 2005;30(10):996-1002. https://doi.org/10.1016/j.psyneuen.2005.03.018
  13. Brown LB, Nicholson TR, Aybek S, Kanaan RA, David AS. Neuropsychological function and memory suppression in conversion disorder. J Neuropsychol. 2014;8(2):171-185. https://doi.org/10.1111/jnp.12017
  14. Walentynowicz M, Raes F, Van Diest I, Van den Bergh O. The Specificity of Health-Related Autobiographical Memories in Patients With Somatic Symptom Disorder. Psychosom Med. 2017;79(1):43-49. https://doi.org/10.1097/PSY.0000000000000357
  15. Koelen JA, Eurelings-Bontekoe LH, Kempke S. Cognitive Alexithymia Mediates the Association Between Avoidant Attachment and Interpersonal Problems in Patients With Somatoform Disorder. J Psychol. 2016;150(6):725-742. https://doi.org/10.1080/00223980.2016.1175997
  16. Kano M, Endo Y, Fukudo S. Association Between Alexithymia and Functional Gastrointestinal Disorders. Front Psychol. 2018;9:599. https://doi.org/10.3389/fpsyg.2018.00599
  17. Vermeulen N, Luminet O. Alexithymia factors and memory performances for neutral and emotional words. Personality and Individual Differences. 2009;47(4):305-309. https://doi.org/10.1016/j.paid.2009.03.018
  18. Waller E, Scheidt CE. Somatoform disorders as disorders of affect regulation: a development perspective. Int Rev Psychiatry. 2006;18(1):13-24. https://doi.org/10.1080/09540260500466774
  19. van Dijke A, Ford JD. Adult attachment and emotion dysregulation in borderline personality and somatoform disorders. Borderline Personal Disord Emot Dysregul. 2015;2:6. https://doi.org/10.1186/s40479-015-0026-9
  20. Del Río-Casanova L, González-Vázquez AI, Justo A, Andrade V, Páramo M, Brenlla J, Blanco-Hortas A. The role of emotion dysregulation in Conversion Disorder. Actas Esp Psiquiatr. 2018;46(3):92-103.
  21. Alekseev AA, Rupchev GE. Ponyatie ob ispolnitel’nykh funktsiyakh v psikhologicheskikh issledovaniyakh: perspektivy i protivorechiya. Psikhologicheskie Issledovaniya: Elektron. Nauch. Zhurn. 2010;4(12). (In Russ.) http://psystudy.ru 0421000116/0036
  22. Zotov MV. Mekhanizmy regulyatsii poznavatel’noi deyatel’nosti v usloviyakh emotsional’nogo stressa. SPb.: Rech’; 2012. (In Russ.)
  23. Gross JJ. Emotion regulation: Affective, cognitive, and social consequences. Psychophysiology. 2002;39:281-291. https://doi.org/10.1017/S0048577201393198
  24. Garnefski N, Kraaij V, Spinhoven P. Negative life events, cognitive emotion regulation and emotional problems. Personality and Individual Differences. 2001;30(8):1311-1327. https://doi.org/10.1016/S0191-8869(00)00113-6
  25. Garnefski N, Kraaij V. Specificity of relations between adolescents’ cognitive emotion regulation strategies and symptoms of depression and anxiety. Cogn Emot. 2018;32(7):1401-1408. https://doi.org/10.1080/02699931.2016.1232698
  26. Banks SJ, Eddy KT, Angstadt M, Nathan PJ, Phan KL. Amygdala-frontal connectivity during emotion regulation. Soc Cogn Affect Neurosci. 2007;2(4):303-312. https://doi.org/10.1093/scan/nsm029
  27. Secades JJ. Citicoline: pharmacological and clinical review. Rev Neurol. 2016;63(3):1-73.
  28. Shavlovskaya OA. Citicoline: new therapeutic possibilities. Lechashchii Vrach. 2014;10:29-33. (In Russ.)
  29. Mashin VV, Belova LA, Dudikov EM, Bergel’son TM, Lankov VA, Zakuraeva KA. Effektivnost’ preparata rekognan u patsientov v ostrom periode ishemicheskogo insul’ta. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;10:44-48. (In Russ.)
  30. Nemkova SA, Semenov DV, Petrova EA, Savchenko DV, Zavadenko NN, Vozvyshaeva MYu, Kanishcheva AS, Ralleva AV, Loginova EM, Tsvetkov DA, Charikova EV, Romanenko NI, Zagar’yan DA, Boldyrev VG. Cognitive and emotional disorders in university students and teachers: the possibility of treatment with recognan (citicoline). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;12:11-18. (In Russ.) https://doi.org/10.17116/jnevro201811812111
  31. Gareri P, Castagna A, Cotroneo AM, Putignano S, De Sarro G, Bruni AC. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clin Interv Aging. 2015;10:1421-1429. https://doi.org/10.2147/cia.s87886
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.